Anna Rose Welch articles

  1. How This Medicare Part D Proposal Gives Biosimilars Chance To Shine
    11/21/2017

    Establishing new language requiring a portion of rebates to be passed on to consumers at the point-of-sale could bode well for biosimilar makers, and especially those that provide a competitive price.

  2. Why The FTC, FDA Collaboration Should Interest Biosimilar Makers
    11/16/2017

    A recent FTC workshop on competition in prescription drug markets reflected a particularly interesting and exciting evolution within the regulatory space. And that has to do with what I consider to be growth in the FDA’s purview as a regulator.

  3. How Biosimilar Companies Can Meet Patients’ Education Needs
    11/13/2017

    What do patient groups want from biosimilar manufacturers, and what advice can they give companies to help shape their initiatives to educate stakeholders?

  4. Biosimilar Education: Perspectives From 4 Patient Advocacy Groups
    11/8/2017

    In the first of this two-part article, four patient advocacy groups share the level of knowledge their members have surrounding biosimilars and what types of strategies they have enacted to educate their patients.

  5. DIA Biosimilars Conference Reveals “More Questions Than Answers”
    10/31/2017

    During the DIA Biosimilars 2017 conference, there were three topics of discussion that, arguably, could remove barriers to biosimilar development and advance it. But a phrase that was regularly used over the two days highlights one of the biggest issues standing in front of this industry: “There are more questions than answers.”

  6. Pfizer’s Cultural Evolution To “Tell The Biosimilar Story”
    10/26/2017

    Pfizer's Tracy Dianis presents a candid look into the cognitive and cultural transition that needed to occur in her own mindset, as well as within Pfizer, in order to embrace biosimilar development.

  7. Biosimilar Regulatory Best Practices: Don’t Fear Exploration
    10/12/2017

    In the first of this two-part article, Sandoz's Cindy Cao shares lessons learned from working with the FDA and reveals that there is still a lot of room for exploration and innovation in biosimilar development.

  8. How Can Biosimilars Remain Politically Relevant?
    9/29/2017

    What does the biosimilar industry need to do now to ensure it’s a relevant and central part of current and future healthcare reform?

  9. What These Two Mottos Must Mean For The Biosimilar Industry
    9/20/2017

    I recently attended the Association for Accessible Medicines (AAM) Biosimilars Council’s Leading on Biosimilars conference.In addition to the many tidbits of knowledge I took away from this event, two terms kept resurfacing throughout the conference I feel are worth delving into more deeply.

  10. Pfenex’s New CEO Sizes Up Biosimilar Industry’s Future
    9/11/2017

    Newly-appointed Pfenex CEO, Eef Schimmelpennink, faces the challenge of determining how to adapt Pfenex to a constantly changing future. Though it's still very early in his tenure, Schimmelpennink highlights some areas he will keep in mind as he steers Pfenex's future biosimilars onto the market.